Guidant shareholder suit dismissed
This article was originally published in Clinica
A US court in Indianapolis has granted Guidant a welcome breather by dismissing a high-end securities fraud lawsuit. The company was slapped with the charge shortly after emerging from the Ancure scandal, in which Guidant's subsidiary, Endovascular Technologies, pleaded guilty to covering up defects in its endovascular stent graft (see Clinica No 1062, p 1).
You may also be interested in...
Circassia is returning the US rights to two COPD drugs to AstraZeneca as it admits it cannot meet its debt payments from the deal.
At their second meeting on COVID-19, drug regulators from around the world have stressed the importance of large, multi-arm studies in generating the data needed for the approval of potential coronavirus therapies. The European Medicines Agency, which organized the meeting, has also announced a new coronavirus task force to identify promising drug candidates and help steer them through development to regulatory approval.